Literature DB >> 15247126

Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women.

Cara L Frankenfeld1, Anne McTiernan, Erin J Aiello, Wendy K Thomas, Kristin LaCroix, Judy Schramm, Stephen M Schwartz, Victoria L Holt, Johanna W Lampe.   

Abstract

Circulating hormones are associated with mammographic density, an intermediate marker of breast cancer risk. Differences in circulating hormones, including estrone and testosterone, have been observed in premenopausal women based on their capacity to metabolize daidzein, an isoflavone found predominantly in soybeans. Equol and O-desmethylangolensin (O-DMA) are products of intestinal bacterial metabolism of daidzein. There is interindividual variability in the capacity to produce daidzein metabolites; individuals can be equol producers or non-producers and O-DMA producers or non-producers. We tested the hypothesis that daidzein-metabolizing phenotypes are associated with mammographic density. Participants were recruited from among 92 sedentary, postmenopausal women, ages 50 to 75 years, who participated in a 1-year physical activity intervention. Pre-intervention mammographic density was determined using a computer-assisted, gray-scale thresholding technique. Fifty-five of these women consumed supplemental soy protein (>10 mg daidzein/d) for 3 days and collected a first-void urine sample on the fourth day to determine daidzein-metabolizing phenotypes. Equol and O-DMA concentrations were measured using gas chromatography-mass spectrometry. Associations between daidzein-metabolizing phenotypes and percent mammographic density were adjusted for age, maximum adult weight, gravidity, family history of breast cancer, and serum follicle-stimulating hormone and free testosterone concentrations. Mammographic density was 39% lower in equol producers compared with non-producers (P = 0.04). O-DMA producers had mammographic density 69% greater than non-producers (P = 0.05). These results suggest that particular intestinal bacterial profiles are associated with postmenopausal mammographic density, and these associations are not entirely explained by differences in reproductive or anthropometric characteristics or circulating hormones.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247126

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

Review 1.  Does equol production determine soy endocrine effects?

Authors:  Dana Shor; Thozhukat Sathyapalan; Stephen L Atkin; Natalie J Thatcher
Journal:  Eur J Nutr       Date:  2012-02-25       Impact factor: 5.614

2.  Equol-producing status, isoflavone intake, and breast density in a sample of U.S. Chinese women.

Authors:  Marilyn Tseng; Celia Byrne; Mindy S Kurzer; Carolyn Y Fang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-09       Impact factor: 4.254

Review 3.  Gut microbes, diet, and cancer.

Authors:  Meredith A J Hullar; Andrea N Burnett-Hartman; Johanna W Lampe
Journal:  Cancer Treat Res       Date:  2014

4.  Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein.

Authors:  C L Frankenfeld; C Atkinson; K Wähälä; J W Lampe
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 5.  Phytoestrogenic isoflavonoids in epidemiologic and clinical research.

Authors:  Adrian A Franke; Brunhild M Halm; Kerry Kakazu; Xingnan Li; Laurie J Custer
Journal:  Drug Test Anal       Date:  2009-01       Impact factor: 3.345

6.  S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Authors:  Mandeep K Virk-Baker; Stephen Barnes; Helen Krontiras; Tim R Nagy
Journal:  Nutr Res       Date:  2013-12-18       Impact factor: 3.315

7.  Is equol the key to the efficacy of soy foods?

Authors:  Johanna W Lampe
Journal:  Am J Clin Nutr       Date:  2009-04-08       Impact factor: 7.045

Review 8.  O-desmethylangolensin: the importance of equol's lesser known cousin to human health.

Authors:  Cara L Frankenfeld
Journal:  Adv Nutr       Date:  2011-06-28       Impact factor: 8.701

9.  Mammographic breast density and serum phytoestrogen levels.

Authors:  Sarah J Lowry; Brian L Sprague; Erin J Aiello Bowles; Curtis J Hedman; Jocelyn Hemming; John M Hampton; Elizabeth S Burnside; Gale A Sisney; Diana S M Buist; Amy Trentham-Dietz
Journal:  Nutr Cancer       Date:  2012-08-03       Impact factor: 2.900

10.  R- and S-equol have equivalent cytoprotective effects in Friedreich's ataxia.

Authors:  Timothy E Richardson; James W Simpkins
Journal:  BMC Pharmacol Toxicol       Date:  2012-10-22       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.